Brilinta

(Ticagrelor)

ApprovedSmall molecule

Ticagrelor is used to prevent blood clots and reduce the risk of heart attack or stroke in people with acute coronary syndrome (a type of severe chest pain or heart problem). It works by making blood less sticky so clots are less likely to form.[2] Brilinta is currently approved and in use across 40 indications[4].[1]

Brilinta is one of 711 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

296

Total Trials

Active Trials

710

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Endothelial DysfunctionActive, not recruiting

Intermediate Coronary SyndromeActive, not recruiting

Cardiac ArrestActive, not recruiting

Angina UnstableActive, not recruiting

Thrombotic DiseaseActive, not recruiting

IschemiaActive, not recruiting

StrokeActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Coronary Artery DiseaseApproved

Active, not recruiting

Cardiovascular DiseasePhase 2

Active, not recruiting

Endothelial DysfunctionApproved

Active, not recruiting

Intermediate Coronary SyndromeApproved

Active, not recruiting

Cardiac ArrestApproved

Active, not recruiting

Angina UnstableApproved

Active, not recruiting

Thrombotic DiseaseApproved

Active, not recruiting

IschemiaPhase 2

Active, not recruiting

StrokePhase 3

Active, not recruiting

Acute Coronary SyndromeApproved

Active, not recruiting

Showing 10 of 37 indications

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Brilinta

AstraZeneca

Approved

1 2

Cimzia

UCB

Preclinical

30 3

Simponi

Johnson & Johnson

Preclinical

19 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Ilaris

Novartis

Preclinical

3 8

Celexa

AbbVie

Preclinical

1 9

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Acute Coronary Syndrome

NCT04240834

Phase 3Recruiting

CABG

NCT03789916

Q4 2028

Post-ApprovalRecruiting

Acute Coronary Syndrome

NCT06451198

Clinical

Trials by Indication[1]

Acute Coronary Syndrome23 trials

Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome

Terminated·YYonsei University·Phase 4·NCT02037412·148 enrolled

Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention

Completed·UUniversity of Patras·Phase 3·NCT01360437·44 enrolled

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT06451198·2,846 enrolled

Show 20 more trials

Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome

Completed·UUniversity Hospital, Ghent·Phase 4·NCT02341729·40 enrolled

TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT03357874·259 enrolled

Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Completed·UUniversity of Patras·Phase 4·NCT01642966·56 enrolled

A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients

Unknown status·SShanghai Tong Ren Hospital·Phase 4·NCT04307485·40 enrolled

Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes

Completed·IIHF GmbH - Institut für Herzinfarktforschung··NCT02265068·700 enrolled

Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome

Unknown status·PPusan National University Yangsan Hospital·Phase 3·NCT01660373·100 enrolled

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Completed·SSeung-Jung Park·Phase 2·NCT02319941·65 enrolled

Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome

Unknown status·AAndalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud··NCT04630288·1,900 enrolled

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Completed·TThorax Centrum Twente··NCT03197298·2,062 enrolled

A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients

Recruiting·SShanghai Tong Ren Hospital·Phase 4·NCT04307511·40 enrolled

Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01294462·801 enrolled

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT03062462·80 enrolled

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT02052635·34 enrolled

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00391872·18,624 enrolled

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Recruiting·FFu Wai Hospital, Beijing, China·Phase 4·NCT04240834·1,220 enrolled

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01603082·343 enrolled

Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT01944800·4,018 enrolled

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02293395·3,037 enrolled

Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Completed·KKorea University Anam Hospital·Phase 4·NCT02487732·60 enrolled

Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome

Completed·TThe University of Hong Kong·Phase 4·NCT01994941·133 enrolled

Clopidogrel15 trials

Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI

Unknown status·RRenJi Hospital·Phase 4·NCT02201667·444 enrolled

Ticagrelor vs. Clopidogrel in Post PCI Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT05858918·476 enrolled

The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man

Completed·MMedical University of Vienna·Phase 2·NCT02120092·89 enrolled

Show 12 more trials

TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI

Unknown status·PPapworth Hospital NHS Foundation Trust·Phase 2·NCT03145194·140 enrolled

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT01826175

Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.

Completed·UUniversity of Patras·Phase 3·NCT01961856·74 enrolled

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT02677545·210 enrolled

Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT02792712·200 enrolled

High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients

Completed·UUniversity of Roma La Sapienza·Phase 3·NCT01543932·81 enrolled

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

Completed·UUniversity of Florida·Phase 4·NCT03437044·40 enrolled

Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Completed·OOttawa Heart Institute Research Corporation·Phase 2/3·NCT01894789·36 enrolled

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02925923·100 enrolled

Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel

Unknown status·RRabin Medical Center·Phase 4·NCT01643031·500 enrolled

COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS

Unknown status·SShenyang Northern Hospital·Phase 4·NCT02578537·60 enrolled

Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI

Unknown status·FFirst Hospital of China Medical University·Phase 4·NCT02233790·600 enrolled

Coronary Artery Disease11 trials

Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease

Completed·UUniversity of Patras·Phase 4·NCT01957540·22 enrolled

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT02889549·60 enrolled

Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

Completed·UUniversity of Florida·Phase 4·NCT02539160·101 enrolled

Show 8 more trials

A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05093790·58 enrolled

An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01118325·146 enrolled

Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor

Completed·UUniversity of Sao Paulo·Phase 2·NCT03039205·90 enrolled

Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

Completed·UUniversity of Florida·N/A·NCT01852175·110 enrolled

The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease

Completed·SShenyang Northern Hospital·N/A·NCT03577652·108 enrolled

The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease

Completed·TThe University of The West Indies·Phase 1/2·NCT04206176·25 enrolled

Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

Completed·UUniversity of Florida·Phase 4·NCT02287909·87 enrolled

Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients

Unknown status·FFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia··NCT02323971·80 enrolled

Myocardial Infarction10 trials

Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction

Unknown status·GGyeongsang National University Hospital·Phase 4·NCT02224534·326 enrolled

Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Completed·—·N/A·NCT02531165·38 enrolled

Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed·UUniversity of Patras·Phase 4·NCT01575795·83 enrolled

Show 7 more trials

Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction

Completed·IInha University Hospital·Phase 4·NCT02026219·76 enrolled

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Completed·UUniversity of Patras·Phase 4·NCT02663713·20 enrolled

Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor

Completed·CCollegium Medicum w Bydgoszczy··NCT03454841·73 enrolled

Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

Recruiting·RRadboud University Medical Center·N/A·NCT05986968·200 enrolled

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

Withdrawn·RRegion Skane·Phase 3·NCT04069234

PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus

Completed·GGennaro Sardella·Phase 3·NCT01531114·50 enrolled

Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed·UUniversity of Patras·Phase 4·NCT01463163·50 enrolled

Acute Myocardial Infarction7 trials

Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

Completed·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT03551964·605 enrolled

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Completed·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT02808767·1,226 enrolled

Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction

Completed·UUniversity of Luebeck·Phase 4·NCT02627950·138 enrolled

Show 4 more trials

Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction

Completed·MMedical University of Warsaw·Phase 4·NCT02931045·60 enrolled

Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

Unknown status·AAmsterdam UMC, location VUmc·Phase 4·NCT02422888·110 enrolled

Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction

Completed·UUniversity of Zagreb·Phase 4·NCT04369534·120 enrolled

Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI

Unknown status·MMina Wageh Mohareb··NCT05911659·60 enrolled

77 more indications

Antiplatelet5 trials

A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01864005·60 enrolled

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00642811·98 enrolled

The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese

Completed·GGuangdong Provincial People's Hospital·Phase 1·NCT03092076·51 enrolled

Show 2 more trials

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

Completed·—·Phase 4·NCT01706510·28 enrolled

P3AMI Antiplatelet Trial

Completed·TThe Royal Wolverhampton Hospitals NHS Trust·Phase 4·NCT02376283·87 enrolled

Coronary Artery Bypass5 trials

Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery

Completed·RRuijin Hospital·Phase 4·NCT02201771·500 enrolled

A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting

Completed·—·Phase 4·NCT02330640·137 enrolled

The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery

Unknown status·JJ.M. ten Berg·Phase 3·NCT02352402·487 enrolled

Show 2 more trials

Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass

Unknown status·YYonsei University·Phase 4·NCT05166538·204 enrolled

Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery

Completed·CCardiology Research UBC·Phase 4·NCT01373411·70 enrolled

Endothelial Function5 trials

Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI

Completed·—·Phase 4·NCT02469740·61 enrolled

ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts

Completed·UUniversity Hospital of Ferrara·Phase 2·NCT02519608·44 enrolled

The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment

Completed·MMichael Wolzt, Prof. MD·Phase 4·NCT02580149·24 enrolled

Show 2 more trials

Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

Unknown status·—·Phase 4·NCT02123004·350 enrolled

The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males

Completed·MMedical University of Vienna·Phase 4·NCT02910778·32 enrolled

Interaction4 trials

Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01350921·22 enrolled

Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01734772·48 enrolled

Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01595854·36 enrolled

Show 1 more trial

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Completed·VViatris Innovation GmbH·Phase 1·NCT03430661·77 enrolled

Percutaneous Coronary Intervention4 trials

Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study

Completed·GGermano Di Sciascio·Phase 4·NCT05643586·50 enrolled

Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention

Completed·PPeking Union Medical College Hospital·Phase 4·NCT02748330·40 enrolled

Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

Completed·TThe First Affiliated Hospital of Dalian Medical University··NCT04999293·1,505 enrolled

Show 1 more trial

Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention

Unknown status·HHyeon-Cheol Gwon·Phase 2·NCT01738100·100 enrolled

Platelet Reactivity4 trials

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

Unknown status·LLifeBridge Health·Phase 4·NCT01869309·400 enrolled

Genotype and Platelet Reactivity in Patients on Hemodialysis

Unknown status·KKyunghee University Medical Center·Phase 3·NCT02394145·20 enrolled

Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

Withdrawn·NNanjing First Hospital, Nanjing Medical University·Phase 3·NCT03078465

Show 1 more trial

High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay

Completed·WWuhan Asia Heart Hospital·N/A·NCT02699008·477 enrolled

Antiplatelet Therapy3 trials

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

Completed·—·Phase 4·NCT02053909·250 enrolled

Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study

Completed·JJohannes Gutenberg University Mainz·Phase 4·NCT01700322·126 enrolled

Tailored Antiplatelet Therapy Following PCI

Completed·MMayo Clinic·Phase 4·NCT01742117·5,276 enrolled

Platelet Function3 trials

Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT01456364·70 enrolled

The ACS Ethnicity Platelet Function Study

Completed·MMedstar Health Research Institute··NCT01829659·4 enrolled

Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile

Completed·UUniversiti Sains Malaysia·Phase 4·NCT05516784·80 enrolled

Peripheral Artery Disease3 trials

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT02121288

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

Completed·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT02325466·70 enrolled

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01732822·13,885 enrolled

Injury3 trials

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Completed·UUniversity of Edinburgh·Phase 2/3·NCT02110303·220 enrolled

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Terminated·TThe Cleveland Clinic·Phase 4·NCT02291419·6 enrolled

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

Completed·AAORTICA Group·N/A·NCT03435133·61 enrolled

Thrombolysis3 trials

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

Withdrawn·—·Phase 4·NCT02048085

Ticagrelor for PCI Post Thrombolysis

Completed·UUnity Health Toronto·Phase 3·NCT01930591·140 enrolled

Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis

Completed·FFederal University of São Paulo·Phase 4·NCT02215993·50 enrolled

Atrial Fibrillation3 trials

The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention

Unknown status·OOttawa Heart Institute Research Corporation·Phase 3·NCT03331484·40 enrolled

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02866175·1,506 enrolled

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01830543·2,124 enrolled

STEMI3 trials

Ticagrelor Pharmacokinetics in NSTEMI

Completed·KKarolinska University Hospital··NCT02292277·63 enrolled

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients

Completed·CCollegium Medicum w Bydgoszczy··NCT02602444·73 enrolled

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI

Unknown status·LLifeBridge Health·Phase 4·NCT02012140·200 enrolled

CABG2 trials

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Unknown status·UUnity Health Toronto·Phase 4·NCT02627521·260 enrolled

SAPT Versus DAPT in Incomplete Revascularization After CABG

Recruiting·—·Phase 3·NCT03789916·800 enrolled

Ischemia2 trials

Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

Terminated·TThe Cleveland Clinic·Phase 2/3·NCT02230527·46 enrolled

Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study

Completed·UUniversity of Southern California·Phase 1/2·NCT02091921·53 enrolled

Hemodialysis2 trials

Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis

Completed·UUniversity of Patras·Phase 3·NCT01511471·20 enrolled

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

Completed·UUniversity of Virginia·Phase 1/2·NCT02335099·54 enrolled

Sickle Cell Disease2 trials

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

Terminated· AstraZeneca logo

AstraZeneca·Phase 3·NCT03615924·193 enrolled

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02482298·87 enrolled

P2Y12 Inhibitor2 trials

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02617290·1,900 enrolled

P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

Terminated·SSamsung Medical Center·Phase 4·NCT03119012·25 enrolled

Aspirin2 trials

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT02270242·9,006 enrolled

GM03 - Platelet RNA Signatures of Aspirin

Completed·—·Phase 1·NCT05278637·135 enrolled

Cardiac Arrest2 trials

Antiplatelet Therapy After Cardiac Arrest

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT02224274·57 enrolled

Add-on Cangrelor in STEMI-triggered Cardiac Arrest

Unknown status·MMedical University of Vienna·Phase 4·NCT03273075·60 enrolled

Function2 trials

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Completed·UUniversity of Florida·Phase 4·NCT03489863·14 enrolled

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Completed·UUniversity of Florida·Phase 4·NCT02065479·65 enrolled

Stroke2 trials

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03354429·11,016 enrolled

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01994720·13,307 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Low-dose Ticagrelor

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT03381742·3,043 enrolled

Efficacy and Safety Study of Ticagrelor

Unknown status·GGeneral Hospital of Chinese Armed Police Forces·Phase 3·NCT01812330·180 enrolled

Intraoperative1 trial

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel

Unknown status·YYongjian Wu·Phase 4·NCT02513004·60 enrolled

Type 2 Diabetes Mellitus1 trial

Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)

Unknown status·SSpanish Society of Cardiology·Phase 4·NCT02457130·30 enrolled

Tics1 trial

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

Completed·TTianjin Institute of Pharmaceutical Research Co., Ltd·Phase 1·NCT06584812·14 enrolled

Peripheral Arterial Disease1 trial

Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit

Unknown status·—·N/A·NCT02762864·200 enrolled

Type 2 Diabetes1 trial

Clopidogrel Versus Ticagrelor in Type-2 Diabetes

Completed·—·Phase 4·NCT02742987·42 enrolled

Oral1 trial

The Effect of IV Cangrelor and Oral Ticagrelor Study

Completed·TThe Royal Wolverhampton Hospitals NHS Trust·Phase 4·NCT02733341·100 enrolled

Chronic Total Occlusion1 trial

TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization

Completed·HHospital Clinic of Barcelona·Phase 4·NCT02211066·59 enrolled

Infusion1 trial

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01919723·70 enrolled

ESS1 trial

Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01504906·20 enrolled

Ventricular Function1 trial

A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study

Completed·HHellenic Cardiovascular Research Society·Phase 3·NCT02429271·336 enrolled

Single Antiplatelet Therapy1 trial

Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

Unknown status·FFu Wai Hospital, Beijing, China·Phase 4·NCT06088433·292 enrolled

ESRD1 trial

ONSET and OFFSET of Ticagrelor in ESRD

Completed·KKyunghee University Medical Center·Phase 3·NCT02163954·16 enrolled

Cardiovascular Disease1 trial

Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2·NCT03487406·120 enrolled

LAM1 trial

Ticagrelor and Anti-inflammatory Effects

Unknown status·KKyunghee University Medical Center·Phase 3·NCT02406911·25 enrolled

Stent Thrombosis1 trial

TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk

Completed·NNational Institute of Cardiovascular Diseases, Pakistan·Phase 4·NCT06667349·1,727 enrolled

Dialysis Patients1 trial

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02022748·27 enrolled

Drug1 trial

Rapid Activity of Platelet Inhibitor Drugs Study 2

Completed·DDavid Antoniucci·Phase 4·NCT01805570·50 enrolled

Morphine1 trial

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

Completed·UUniversity of Florida·Phase 4·NCT02403830·30 enrolled

Intensive Care Unit1 trial

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

Unknown status·MMedical University of Vienna·Phase 2·NCT02285751·200 enrolled

Arterial Stiffness1 trial

Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With CAD.

Completed·HHellenic Cardiovascular Research Society·Phase 2·NCT02071212·120 enrolled

Statin1 trial

A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06554821·28 enrolled

Infiltration1 trial

Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 4·NCT02639143·50 enrolled

Coronary Artery Lesions1 trial

Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions

Unknown status·XXijing Hospital·N/A·NCT05209412·370 enrolled

Stent Implantation1 trial

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Completed·EECRI bv·Phase 3·NCT01813435·15,991 enrolled

Low Molecular Weight Heparin1 trial

The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI

Unknown status·—·Phase 4·NCT02658838·300 enrolled

Rheumatoid Arthritis1 trial

Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis

Completed·NNYU Langone Health·Phase 4·NCT02874092·9 enrolled

Microcirculation1 trial

Comparing Ticagrelor Versus Clopidogrel on Microcirculation

Completed·—·N/A·NCT02618733·120 enrolled

Platelet Aggregation1 trial

Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel

Completed·UUniversity of Sao Paulo·Phase 4·NCT05247385·87 enrolled

Prevention1 trial

Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

Terminated·DDeutsches Herzzentrum Muenchen·Phase 3·NCT01755520·1,893 enrolled

Diabetes1 trial

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

Completed·UUniversity of Florida·N/A·NCT01852214·50 enrolled

Aneurysm1 trial

Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm

Completed·FFondation Ophtalmologique Adolphe de Rothschild·Phase 3·NCT02675205·100 enrolled

Age1 trial

Optimal Dosage of Ticagrelor in Korean Patients With AMI

Unknown status·—·Phase 4·NCT05210595·120 enrolled

Atherosclerotic Plaque1 trial

Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation

Completed·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT01905566·50 enrolled

Cholesterol1 trial

KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug

Unknown status·HHelsinki University Central Hospital·Phase 1·NCT05373277·10 enrolled

Antithrombotic Agents1 trial

OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT01955200·1,724 enrolled

RCT1 trial

Ticagrelor vs. Prasugrel Effects on Infarct Size

Withdrawn·YYochai Birnbaum·Phase 2·NCT02507323

ALK1 trial

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT02227368·40 enrolled

Trial1 trial

Platelet Sub-study of the TWILIGHT Trial

Completed·JJuan Badimon··NCT04001374·40 enrolled

Treatment1 trial

Paradigm Shift in the Treatment of Patients With ACS

Completed·YYu Bo·Phase 4·NCT02041650·250 enrolled

Preconditioning1 trial

Ticagrelor in Remote Ischemic Preconditioning Study

Completed·HHellenic Society of Interventional Cardiology·Phase 4·NCT04174261·245 enrolled

Chronic Coronary Syndrome1 trial

Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients

Unknown status·NNova Scotia Health Authority·Phase 4·NCT05116995·30 enrolled

Platelet Inhibition1 trial

Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI

Unknown status·UUniversity of Aarhus·Phase 4·NCT03182855·80 enrolled

Pneumonia1 trial

Ticagrelor in Severe Community Acquired Pneumonia

Terminated·GGordon Bernard·Phase 2·NCT01998399·25 enrolled

Inflammation1 trial

The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation

Withdrawn·—·Phase 4·NCT02626169

Antithrombotic1 trial

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Recruiting·MMedical University of Gdansk·Phase 4·NCT04695106·2,230 enrolled

Endotoxemia1 trial

Ticagrelor in Human Endotoxemia Response to Human Endotoxemia

Completed·RRadboud University Medical Center·N/A·NCT02612480·40 enrolled

Complication1 trial

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

ART1 trial

Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

Terminated·—·Phase 4·NCT02071966·55 enrolled

Unknown status·NNorth Texas Veterans Healthcare System·Phase 4·NCT03150667·220 enrolled

Endothelial Dysfunction1 trial

Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation

Unknown status·KKiyuk Chang·Phase 4·NCT02379676·38 enrolled

Dual Antiplatelet Therapy1 trial

A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge

Recruiting·—·N/A·NCT06301776·560 enrolled

Unspecified13 trials

Chewed Versus Integral Pill of Ticagrelor

Completed·WWake Forest University Health Sciences·Phase 4·NCT03708588·112 enrolled

TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement

Completed·UUniversity Hospital, Toulouse·Phase 4·NCT02505399·180 enrolled

A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

Withdrawn·CCirQuest Labs, LLC·Phase 4·NCT03027934

Show 10 more trials

Reversal of the Anti-platelet Effects of Ticagrelor

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT02383771·64 enrolled

A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01523366·53 enrolled

Study of LC23-1306 in Healthy Male Subjects

Completed·LLG Life Sciences·Phase 1·NCT01526577·113 enrolled

Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina

Unknown status·SSecond Xiangya Hospital of Central South University·Phase 4·NCT02284048·140 enrolled

Effect of Ticagrelor on Fractional Flow Reserve

Completed·UUniversity of Patras·Phase 4·NCT02108808·76 enrolled

Brilinta DaYu Study

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01870921·2,004 enrolled

Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study

Completed·UUniversity of Patras·Phase 4·NCT01642940·30 enrolled

Cangrelor Ticagrelor Transition Study

Completed· Novartis logo

Novartis·Phase 2·NCT01766466·12 enrolled

NIRS Ticagrelor Evaluation

Completed·MMedstar Health Research Institute·Phase 4·NCT02282332·30 enrolled

A Pharmacodynamic Study With Ticagrelor in African American Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01523392·50 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 3, 2015

BRILINTA

NDA NDA022433

Sources

References

[1]
ClinicalTrials.gov — 296 trial records for Ticagrelor. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Brilinta drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ticagrelor compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ticagrelor. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022433). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Brilinta. U.S. Food & Drug Administration.
[7]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Purinergic Receptor P2Y12 Negative Allosteric Modulator[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AstraZeneca

Patent Landscape[6]

Patent Cliff

Apr 17, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8425934Apr 17, 2030

8425934*PEDOct 17, 2030

10300065Jan 27, 2036

10300065*PEDJul 27, 2036